BioAge Advances NLRP3 Inhibitor BGE-102 with Phase 2 Trial Initiation
Event summary
- BioAge dosed the first participant in QUELL-CV, a Phase 2 trial of BGE-102 for cardiometabolic diseases, with topline data expected in late 2026.
- QUELL-DME, a Phase 1b/2a trial for diabetic macular edema, is planned to start mid-2026 with results anticipated mid-2027.
- BioAge reported Q2 2026 revenue of $2.4M and R&D expenses of $24.4M, up from $19.8M in Q2 2025 due to BGE-102 trial costs.
- The company has $381.3M in cash as of June 30, 2026, sufficient to fund operations through 2029.
The big picture
BioAge is betting heavily on the NLRP3 inhibition mechanism, targeting a range of inflammation-driven diseases. The strategic shift into ocular diseases with QUELL-DME expands its pipeline beyond cardiometabolic conditions. With strong cash reserves and partnerships with Novartis and Lilly ExploR&D, BioAge aims to leverage its aging biology insights for broader therapeutic applications.
What we're watching
- Clinical Efficacy
- Whether BGE-102 can demonstrate significant reductions in hsCRP and other inflammatory biomarkers in the Phase 2 trial.
- Market Expansion
- The pace at which BioAge can expand BGE-102 into additional inflammation-driven diseases beyond cardiometabolic conditions.
- Financial Discipline
- How BioAge manages increasing R&D expenses while maintaining its cash runway through 2029.